정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2522 | Completed | A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | Coronavirus | Drug: Fluvoxamine Drug: Placebo |
Phase 2 | Washington University School of Medicine | OTHER | 152 | All | 18 Years | BJC, Belleville, Illinois, United States Washington University School of Medicine, Saint Louis, Missouri, United States |
2521 | Recruiting | A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | COVID-19; SARS-CoV-2 | Biological: UB-612 | Phase 1 | United Biomedical Inc., Asia, Vaxxinity, Inc. | INDUSTRY | 60 | All | 20 Years ~ 55 Years | China Medical University Hospital, Taichung, Taiwan |
2520 | Recruiting | A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers | Traumatic Brain Injury (TBI) | Drug: PRV-002 Drug: Placebo |
Phase 1 | Odyssey Group International, Inc., Avance Clinical Pty Ltd. | INDUSTRY | 24 | All | 18 Years ~ 55 Years | Nucleus Network Pty Ltd,, Melbourne, Victoria, Australia |
2519 | Recruiting | A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection | COVID-19 | Biological: COVIDITY administered via needle-free injection (PharmaJet Tropis®; intradermal injection). Biological: COVIDITY administered via needle-free injection (PharmaJet Stratis®; intramuscular injection). |
Phase 1 | Scancell Ltd | INDUSTRY | 40 | All | 18 Years ~ 59 Years | University of Cape Town Lung Institute, Centre for TB Research Innovation, Cape Town, Western Cape, South Africa |
2518 | Completed | A First-in-Human Study of AV-001 in Healthy Subjects | ARDS | Drug: AV-001 Other: Placebo |
Phase 1 | Vasomune Therapeutics, Inc. | INDUSTRY | 48 | All | 18 Years ~ 65 Years | Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States |
2517 | Enrolling by invitation | A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) | COVID-19 | Biological: Recombinant COVID-19 vaccine (Sf9 cells) Other: Placebo control |
Phase 3 | WestVac Biopharma Co., Ltd., West China Hospital | INDUSTRY | 40000 | All | 18 Years | Puskesmas Ciketingudik, Bekasi, Jiangsu, Indonesia Permata Hospital, Bekasi, Indonesia Brawijaya University Hospital, Malang, Indonesia Universitas Muhammadiyah Malang Hospital, Malang, Indonesia Airlangga University Hospital, Surabaya, Indonesia Husada Utama Hospital, Surabaya, Indonesia Moi Teaching and Referral Hospital,Eldoret (MTRH), Eldoret, Kenya KAVI-Institute of Clinical Research, University of Nairobi, Nairobi, Kenya Hospital General Dr. Manuel Gea Gonzalez, Ciudad de Mexico, Mexico Invesclinic MX, Ciudad de Mexico, Mexico Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico Centro de Investigacion Clinica y medicina traslacional (CIMeT), Guadalajara, Mexico Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C., Morelia, Mexico SMIQ,S de R.L. de C.V., Queretaro, Mexico FS Scientia Pharma SA de CV, San Luis Potosi, Mexico Perpetual Succour Hospital - The Research Institute, Cebu City, Philippines De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines The Medical City - Iloilo, Iloilo City, Philippines West Visayas State University Medical Center, Iloilo City, Philippines Tropical Disease Foundation, Makati City, Philippines Quirino Memorial Medical Center, Quezon City, Philippines St Luke Medical Centre - BGC, Taguig, Philippines |
2516 | Recruiting | A Heterologous 3rd Boost of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With 2 Doses of ChAdOx1-nCov-19 | COVID-19 Vaccine | Biological: MVC-COV1901(3 Months) Biological: MVC-COV1901(6 Months) |
Phase 4 | Taoyuan General Hospital, Medigen Vaccine Biologics Corp. | OTHER_GOV | 200 | All | 20 Years ~ 64 Years | Taoyuan General Hospital, Taoyuan, Taiwan |